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Aberrant methylated key genes of 
methyl group metabolism within 
the molecular etiology of urothelial 
carcinogenesis
Lars Erichsen1, Foued Ghanjati1, Agnes Beermann1, Cedric Poyet2, Thomas Hermanns2, 
Wolfgang A. Schulz3, Hans-Helge Seifert4, Peter J. Wild5, Lorenz Buser5, Alexander Kröning1, 
Stefan Braunstein6, Martin Anlauf6, Silvia Jankowiak6, Mohamed Hassan7,8, Marcelo L. 
Bendhack9, Marcos J. Araúzo-Bravo  10,11 & Simeon Santourlidis1
Urothelial carcinoma (UC), the most common cancer of the urinary bladder causes severe morbidity 
and mortality, e.g. about 40.000 deaths in the EU annually, and incurs considerable costs for the 
health system due to the need for prolonged treatments and long-term monitoring. Extensive 
aberrant  DNA methylation is described to prevail in urothelial carcinoma and is thought to contribute 
to genetic instability, altered gene expression and tumor progression. However, it is unknown how 
this epigenetic alteration arises during carcinogenesis. Intact methyl group metabolism is required to 
ensure maintenance of cell-type specific methylomes and thereby genetic integrity and proper cellular 
function. Here, using two independent techniques for detecting DNA methylation, we observed DNA 
hypermethylation of the 5′-regulatory regions of the key methyl group metabolism genes ODC1, AHCY 
and MTHFR in early urothelial carcinoma. These hypermethylation events are associated with genome-
wide DNA hypomethylation which is commonly associated with genetic instability. We therefore infer 
that hypermethylation of methyl group metabolism genes acts in a feed-forward cycle to promote 
additional DNA methylation changes and suggest a new hypothesis on the molecular etiology of 
urothelial carcinoma.
Urothelial carcinoma (UC), the most common cancer of the urinary bladder, causes severe morbidity and sub-
stantial mortality. Each year, approximately 110 500 men and 70 000 women are diagnosed with the disease and 
38 200 patients in the European Union and 17 000 patients in the US die from UC1. Approximately 75% of bladder 
cancer is non-muscle invasive (NMI) UC at the time of diagnosis, of which 70% present as noninvasive, papillary 
tumors confined to the mucosa (pTa), 20% as tumors invading the subepithelial tissue (pT1), and 10% as flat dys-
plastic (carcinoma in situ, or CIS) lesions2. High grade (HG) tumors carry a worse prognosis than low-grade (LG) 
tumors. Relapse rates typically range from 30% to 70% with rates of progression as high as 10–30% for high-grade 
tumors3. Furthermore, due to this high tendency towards relapsing, UC places an enormous burden on health 
care systems3. About one-third of all bladder cancers occur as multifocal disease with several tumors forming at 
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different sites of the bladder wall4. It is thought that a “field defect” underlies both high relapse rates and mul-
tifocality. According to this hypothesis, urothelial cells in regions adjacent to the tumors are already primed to 
undergo transformation because their genetic integrity has been already disturbed by environmental mutagens4.
DNA methylation is a fundamental epigenetic mechanism, involved in organization of the genome and medi-
ating effects of environmental influences on adaptive regulation of gene expression5,6. Exposure to harmful envi-
ronmental stimuli can affect proper epigenetic gene regulation and as a consequence can lead to impairment of 
cellular differentiation and functions.
In urothelial carcinoma, focal DNA hypermethylation events, often associated with gene repression, and 
genome-wide LINE-1 hypomethylation have been detected in non-muscle invasive as well as in more aggressive 
muscle-invasive tumors7,8. LINE-1 hypomethylation is present in up to 90% of UC9 and has been pursued as a 
potential potent biomarker for early diagnosis of UC and monitoring of recurrent disease. It may contribute to 
carcinogenesis in various ways, including induction of genomic instability10 and aberrant transcription patterns11.
Exposure to various chemical carcinogens such as occupational exposure to aromatic amines, and polycyclic 
aromatic hydrocarbons, with different attributable risks, is recognized as an important risk factor in urothe-
lial carcinogenesis1. In addition, exposure to arsenic in drinking water and aristolochic acid in food or reme-
dies, have been recognized as further causes of UC. The single main risk factor for bladder cancer is tobacco 
smoking12, which is estimated to account for 50% of tumors13. Tobacco smoke contains aromatic amines, such 
as 2-naphthylamine, and polycyclic aromatic hydrocarbons that are renally excreted and exert their carcino-
genic effect on the entire urinary tract. They are thought to act as carcinogens by forming DNA adducts and 
causing mutations in key cancer-related genes14. Consequently quitting smoking reduces bladder cancer risk. 
Furthermore, higher fluid intake may reduce exposure of urothelial tissue to these carcinogens by diluting urine 
and increasing the frequency of micturition1. Indeed, Michaud et al. presented a case-control study finding water 
intake to be inversely associated with bladder UC risk15.
Accumulating evidence indicates that aberrant DNA methylation occurs as a direct consequence of exposure 
of urothelial cells to tobacco smoke carcinogens in urine16. For instance, in an in vitro model tobacco smoke 
induced the stepwise transformation of urinary tract epithelial cells with concomitant hypermethylation of many 
genes17. Similarly, several studies have linked arsenic exposure with hypermethylation and hypomethylation 
events in urothelial carcinogenesis (see refs in Schulz & Goering8).
Consequently it has been suggested that one main goal of an urologist should be to inform smoking patients 
on the causative factors of UC and to strongly counsel to stop smoking18.
Despite these insights, the mechanisms leading to the progressive changes in DNA methylation during urothe-
lial carcinogenesis are still largely unclear. We were therefore intrigued to observe during a screen for DNA meth-
ylation alterations in early stage urothelial carcinoma and adjacent, morphologically normal urothelium that 
genes encoding crucial enzymes in methyl group metabolism pathways appeared themselves to be affected by 
aberrant DNA methylation. To follow up on this observation, we applied two independent techniques for the 
detection of DNA methylation. The results indeed provide evidence that key genes of methyl group metabo-
lism are themselves affected by aberrant DNA methylation in their 5′-regulatory regions in early stage urothe-
lial carcinoma. These findings implicate a new mechanism in the etiology of epigenetic alterations during UC 
carcinogenesis.
Results
Detection of differential methylated key genes of methylgroup metabolism by global DNA 
methylation array analyses in UC. There is evidence that tumor adjacent uroepithelium, although it 
might pathologically be reviewed to consist of healthy uroepithelial cells, is already in a premalignant state which 
is characterized by genetic, e.g. TP53 mutant cells4, and widespread epigenetic alterations, e.g. hypermethylated 
genes which are also present in bladder cancer cells19. It has been suggested that this “field defect” predispose 
the epithelial tissue to undergo transformation and might underlie tumor recurrence and multifocality, both 
hallmarks of bladder cancer. Genome-wide DNA methylation data sets were generated from pathologically clas-
sified UC, tumor-adjacent normal-appearing and healthy urothelial tissue samples by MeDIP and promoter array 
analyses (see methods). The reference group, to which all other groups were compared, consisted of 4 tissue 
samples of healthy urothelium. The other 4 groups of tissue samples respectively consisted of 10 specimens of UC 
from unifocal papillary tumors (UT), 4 specimens adjacent to unifocal tumors, histologically verified as normal 
urothelium (badj UT), 5 tissue specimens of UC from multifocal tumors (MT) and 5 specimens adjacent to mul-
tifocal tumors, histologically verified as normal urothelium (badjMT) (Table 1).
For each individual sample, integrated peak values for overall methylation of CpG-islands associated with the 
5′-regions of methyl group metabolism genes were obtained. Mean values of these peak values were calculated 
for each sample group. Supplementary Fig. 1 exemplarily illustrates the detailed differences of mean peak values 
of 4 differentially methylated genes of each group. The statistical significance of differentially methylated regions 
(DMRs) was calculated for each group of samples compared to the healthy urothelium reference, based on the 
mean peak values by two-sample Student’s t-test with a significance threshold αDMR = 0.05. The results are sum-
marized in Fig. 1 and provide a first overview of these differentially methylated genes (Fig. 1). They can be divided 
into 3 main groups. Twelve of 26 considered genes did not show statistically significant differential methylation 
in any of the sample groups compared to healthy urothelium, despite a trend towards hypermethylation in ARG1, 
BHMT, BHMT2, CBS, DNMT3A, DNMT3B, FOLR3, SHMT1 and SMOX, and a trend towards hypomethylation 
in FOLR1/2 and MAT2B and in the corresponding tumor-adjacent, histologically benign urothelium.
The second group consisted of genes with statistically significant hypermethylation in either unifocal or mul-
tifocal tumors, namely AMD1, DNMT1 and MGMT in unifocal tumors and UHRF1, AHCYL1 and TCN2 in 
multifocal tumors. Noteworthy, MGMT was also significantly hypermethylated in histologically benign urothe-
lial tissue samples adjacent to unifocal tumors. GNMT, DNMT3l, MAT2A, and SMS were hypomethylated in 
www.nature.com/scientificreports/
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multifocal tumors, and the last three of these genes were also hypomethylated in the multifocal tumors adjacent, 
histologically benign urothelial tissue samples.
Finally ODC1, AHCY, MTHFR and AHCYL2 were significantly hypermethylated in their 5′-regulatory gene 
regions in unifocal as well as multifocal tumors. Significant hypermethylation of ODC1, MTHFR and AHCYL2 
occured also in the tumor adjacent, histologically benign urothelial tissue samples (Fig. 1). The differential meth-
ylation of these genes in bladder cancer was not apparent in previously published data by other groups (see 
refs19–22). However, a direct comparison with The Cancer Genome Atlas (TCGA) expression dataset on the other 
hand revealed significant lower expression of the hypermethylated genes MTHFR and ODC1 but not of AHCY in 
bladder cancer samples (Suppl. Figure 3).
Verification of DNA methylation changes of ODC1 and AHCY in UC by bisulfite sequencing. In 
order to confirm the hypermethylation detected in ODC1 and AHCY by MeDIP-array analyses and to reveal 
the detailed methylation patterns of these differentially methylated regions (DMRs) we used standard bisulfite 
sequencing. Specifically, ODC1 hypermethylation had been detected in two pTaLG (2xMT), in two pTaLGadj 
(1xMT, 1xUT), in three pTaHG (1xMT, 2xUT), in two pTaHGadj (2xUT), in four pT1HG (2xMT, 2xUT), and 
in three pT1HGadj (1xMT, 2xUT) tissue samples. Exemplarily, bisulfite sequencing confirmed complete lack 
of DNA methylation of the CpG-rich ODC1 5′-region in three DNA samples from healthy urothelium (Fig. 2). 
Conversely, dense methylation of the same region was exemplarily confirmed for one pTa low grade and one 
pTa high grade UC samples (Fig. 2). In addition, dense methylation was also confirmed in one low and two high 
grade primary pT1 UC tissue samples (Fig. 2). In all these cases DNA methylation array data had indicated DNA 
hypermethylation of the respective ODC1 5′-regulatory region. Noteworthy, two pT1 samples identified as not 
hypermethylated in the array analysis were also completely unmethylated according to bisulfite sequencing (data 
not shown). Thus, hypermethylation at the 5′-region of ODC1 appears to occur in some, but not all early stage 
urothelial carcinoma specimens.
According to the array analysis, the CpG-island across the AHCY 5′-regulatory region was completely 
unmethylated in intact, healthy urothelium samples, whereas AHCY hypermethylation was detected in the fol-
lowing tissue samples: 4 pTaLG (2xMT, 2xUT), 1 pTaLGadj (MT), 3 pTaHG (1xMT, 2xUT), 3 pTaHGadj (3xUT), 
1 pT1LG (UT), 1 pT1HG (MT), 2pT1HGadj (1xMT, 1xUT). We confirmed by bisulfite sequencing dense DNA 
methylation of this region in one unifocal pTa low grade, one multifocal pTa low grade and one unifocal pT1 low 
grade UC tissue sample and in contrast, lack of methylation in intact, healthy urothelium (Fig. 3). In addition, we 
Sample ID Stage/Grade Localisation Sample origin
35396 Healthy bladder tissue — microdissection
1229–4 Healthy bladder tissue — microdissection
AC1 Healthy bladder tissue — punch
AC3 Healthy bladder tissue — punch
30833 pTa LG unifocal microdissection
28923 pTa LG unifocal punch
108T pTa LG unifocal punch
105T pTa HG unifocal punch
111T pTa HG unifocal punch
28643 pT1 LG unifocal punch
29986 pT1 HG unifocal punch
00156 pT1 HG unifocal punch
151T pT1 HG unifocal punch
28774 pT3 HG unifocal microdissection
108NT pTa LG adjacent unifocal punch
105NT pTa HG adjacent unifocal punch
111NT pTa HG adjacent unifocal punch
151NT pT1 HG adjacent unifocal punch
51T pTa LG multifocal punch
148T pTa LG multifocal punch
84T pTa HG multifocal punch
63T pT1 HG multifocal punch
103T pT1 HG multifocal punch
51NT pTa LG adjacent multifocal punch
148NT pTa LG adjacent multifocal punch
84NT pTa HG adjacent multifocal punch
63NT pT1 HG adjacent multifocal punch
103NT pT1 HG adjacent multifocal punch
Table 1. Overview of used healthy and tumor-adjacent urothelial and UC tissue samples.
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confirmed complete lack of methylation in one multifocal pT1 high grade UC sample in accord with the array 
data. Thus dense DNA methylation occurs in this gene too, in some early urothelial carcinoma specimens.
Whereas the array analysis detected strong differences in the methylation of ODC1 and AHCY, less clear-cut 
differences were observed in other genes. To validate these changes as well by an independent technique, we delib-
erately chose one of several samples with slight hypermethylation of the CBS gene according to the MeDIP-array 
analysis for validation by bisulfite sequencing. In this case, too, the marginal methylation increase in a microdis-
sected, unifocal pT3 UC tissue sample was confirmed, whereas a healthy urothelium specimen was unmethylated 
in accord with the corresponding DNA methylation array data (Fig. 4). Thus, genomic bisulfite sequencing data 
consistently confirmed the corresponding DNA methylation array data in all investigated cases.
Figure 1. Differences in methylation in 5′ regulatory regions of key methyl group metabolism genes in 
urothelial carcinoma. Differentially methylated regions (DMRs) were detected by MeDIP/promoter array 
analyses applied on 4 reference specimens of healthy urothelium, compared to 10 UC tissue specimens from 
unifocal tumors (UT), 4 specimens adjacent to a unifocal tumor, histologically verified as benign, normal 
urothelial tissue (badj UT), 5 UC tissue specimens from multifocal tumors (MT) and 5 specimens adjacent to 
a multifocal tumor, histologically verified as benign, normal urothelial tissue (badj MT). Statistical significance 
of the detected differential methylation in the tumors and tumor adjacent tissue groups was evaluated using 
the two sample Student’s t-test. The table lists p-values and fold-changes in parentheses. Values of significant 
occurrence are highlighted in red. “+” stands for hypermethylation and “−” represents hypomethylation of the 
respective gene’s DMR.
www.nature.com/scientificreports/
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Unusual focal non-CpG methylation in the 5′-regulatory MTHFR region in early UC. Whereas 
the reference samples of healthy urothelium lacked methylation according to methylation array analysis, DNA 
methylation was detected at the MTHFR 5′-regulatory region in the following samples: 1 pTaLG (MT), 2pTaL-
Gadj (1xMT, 1xUT), 2 pTaHG (2UT), 2pTaHGadj (2UT), 2 pT1HG (1xMT, 1xUT), 2pT1HGadj (1xMT, 1xUT). 
Accordingly, bisulfite sequencing revealed increased methylation in one examined unifocal pT1 low grade and 
in two unifocal pT1 high grade UC tissue specimens compared to one healthy urothelium sample and one pT1 
tumor adjacent, benign urothelial tissue specimen (Fig. 5). In the pT1 low grade UC tissue we found all sequences 
uniformly methylated at cytosine position −321 relative to the transcription start side (NCBI Reference Sequence: 
NG_013351.1). In both pT1 high grade samples all sequences contained methylated cytosine nucleotides at posi-
tions −346, −156 and −122. In the healthy urothelium sample we found only a methylated cytosine at position 
−321 in a few of the sequences. Thus some early UC samples contained an unusual focal cytosine methylation in 
the MTHFR 5′-regulatory region. Noteworthy, by in silico comparison of the differentially methylated nucleotide 
positions and their sequence contexts with the transcription factor binding sites data bank Promo23 we found the 
Figure 2. Detailed analyses by bisulfite sequencing of CpG island methylation patterns within 5′ regulatory 
region of ODC1 gene in early urothelium carcinoma. Stage and grade of UC tissue specimens with sample 
IDs (Table 1) are depicted above the panels. Exemplified above the first two panels, two corresponding array 
results are shown by bar plots. Each blue bar represents a 75 bp long CpG rich probe on the array. The high 
of a bar is proportional to methylation degree. Below the detailed CpG methylation profiles of the ODC1 
5′-regulatory region are documented as revealed by bisulfite sequencing. Filled circles stand for methylated 
CpG dinucleotides. White cyrcles stand for unmethylated CpGs. Crossed cyrcles stand for undefined CpG 
methylation status. Arrows indicate the transcription start site of ODC1 gene.
www.nature.com/scientificreports/
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cytosines −156 and −122 to be located within a predicted glucocorticoid receptor binding site with a dissimilar-
ity margin less than 9%.
LINE-1 hypomethylation in early stage UC. Global hypomethylation in the tissue specimens was meas-
ured by quantifying relative LINE-1 DNA methylation in the examined tissue samples by idiolocal normalized 
real-time methylation specific PCR24. This method allows a reliable comparison of LINE-1 methylation in tumor 
samples despite genetic heterogeneity and copy number changes10. Most UC tissues displayed marked hypometh-
ylation in comparison to normal healthy urothelium (Fig. 6).
Discussion
Urothelial carcinoma is broadly documented in the literature (reviewed by Schulz et al.)25 as a tumor entity 
with numerous and diverse epigenetic aberrations and associated genetic abnormalities that are thought to 
originate in the early stages of the carcinogenesis process and spreading across the entire genome. It should be 
emphasized that consequently the latter vastly interfere with and largely hamper reliable and comparative gene 
expression analyses in UC samples of different individuals, since it is technically not practicable to define before-
hand any measurement, the actual copy numbers, neither of genetic loci of interest, nor, where methodically 
required, of endogenous references. For instance relative quantification of gene transcription using the common 
ΔΔct-Method which uses an endogenous reference gene will inevitably lead to a measured higher expression of 
the gene of interest if the reference locus is affected by loss of heterozygosity (LOH) and therefore by diminished 
transcription24.
Urothelial carcinoma is thought to be caused by chemical carcinogens. For instance, tobacco smoking, a main 
risk factor, is thought to exert its adverse effect by aromatic amines and other contained carcinogens, reaching 
urothelial cells via the urine, forming DNA adducts and causing mutations. The precise mechanisms are however 
Figure 3. Detailed analysis by bisulfite sequencing of CpG island methylation patterns within 5′ regulatory 
region of AHCY gene in early urothelium carcinoma. Stage and grade of UC tissue specimens with sample IDs 
(Table 1) are depicted above the panels. Exemplified above the first two panels, two corresponding array results 
are shown by bar plots. Each blue bar represents a 75bp long CpG rich probe on the array. The high of a bar 
is proportional to methylation degree. Underneath the detailed CpG methylation profiles of the CpG rich 5′ 
regulatory region of AHCY gene are documented as they were revealed by bisulfite sequencing. Filled circles 
stand for methylated CpG dinucleotides. White circles stand for unmethylated CpG. Crossed out circles stand 
for undefined CpG methylation status. Arrows indicate the transcription start site of AHCY gene. The red bar 
within the above, right bar diagram indicates that the corresponding value is 3200 and thus beyond the scale.
www.nature.com/scientificreports/
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not fully understood14. Even less understood is the origin of epigenetic aberrations, although some have recently 
been linked to chemical carcinogens (reviewed in Schulz & Goering)8.
In the present manuscript, we provide evidence that genes encoding key factors of methyl group metabolism 
could be among the first genes epigenetically altered during urothelial carcinogenesis. Specifically, using two 
independent techniques, we found increased DNA methylation within the promoter regions of the genes ODC1, 
ACHY, and MTHFR in early stage urothelial carcinoma tissues. As a consequence these genes may become epi-
genetically transcriptionally silenced or repressed. All three gene products influence the crucial cellular ratio 
of S-adenosyl-L-methionine (SAM) to S-adenosyl-L-homocysteine (SAH). SAM is the methyl group donor for 
many cellular methylation reactions, but especially for DNA methylation. SAH is generated from SAM in these 
reactions and efficiently inhibits SAM-dependent methyltransferases26. Accordingly, significantly decreased SAM 
levels or significantly increased SAH levels, i.e. any significant decrease of the SAM:SAH ratio leads to global 
DNA hypomethylation26. Global hypomethylation is a characteristic of many cancers, related to genomic insta-
bility27,28 and is particularly prominent in urothelial carcinoma29. Therefore, the hypermethylation of key methyl 
group metabolism genes in early urothelial carcinoma specimens may promote further epigenetic alterations 
such as global DNA hypomethylation. Beyond their possible involvement in the molecular etiology of the disease, 
DNA methylation changes in methyl group metabolism genes may be useful for diagnostic and prognostic pur-
poses, monitoring of treatment and recurrence, and for the classification of urothelial carcinoma.
The first enzyme affected by these hypermethylation events, ODC1, ornithine decarboxylase, is the 
rate-limiting enzyme of polyamine biosynthesis. It thus belongs to the group of ‘housekeeping’ enzymes that are 
expressed in practically all tissues. Its 5′-regulatory region, which has been shown to be crucial for expression30, 
encompasses a CpG-island which should be always free of methylation.
In early work, a positive correlation between ODC1 gene hypomethylation and expression was observed31, 
experimental methylation of ODC1 abolished expression32 and aberrant methylation was reported in malignant 
cells33. Accordingly, we demonstrated here that the 5′-regulatory region of ODC1 is hypermethylated in early UC 
(Fig. 2), has indeed promoter activity and that it can be efficiently repressed by DNA methylation (Supplementary 
Fig. 2a). ODC is tightly regulated at the protein level by multiple mechanisms34 that control its very rapid turn-
over, implying that transcriptional downregulation could lead to diminished enzyme activity within the cell. 
Interestingly, analysis of the pan-cancer TCGA data reveals that ODC1 expression in bladder cancer is among 
the lowest of any cancer type and substantially decreased compared to normal bladder cancer tissues (Suppl. 
Figure 3). ODC1 is linked to methyl group metabolism by the observation that interference with ODC1 enzyme 
activity results in accumulation of SAH and decarboxylated S-adenosylmethionine (dcSAM), which likewise acts 
as a competitive inhibitor of methylation reactions, resulting in genome-wide DNA demethylation, as shown e.g. 
in human oral cancer cells35,36. Thus, the dense DNA methylation encompassing the ODC1 5′-regulatory region 
Figure 4. Detailed analysis by bisulfite sequencing of CpG island methylation patterns within 5′- regulatory 
region of CBS gene in urothelium carcinoma. Stage and grade of UC tissue specimens with sample IDs (Table 1) 
are depicted above the panels. Above the first two panels, two corresponding array results are shown as bar 
plots. Each blue bar represents a 75 bp long CpG rich probe on the array. The height of a bar is proportional 
to the methylation degree. Underneath the corresponding detailed CpG methylation profiles of the CpG-rich 
5′ regulatory region of CBS gene are documented as they were revealed by bisulfite sequencing from healthy 
urothelium and a pT3 UC tissue sample. Filled circles stand for methylated CpG dinucleotides. White circles 
stand for unmethylated CpG. Percentages in parentheses are indicating the respective methylated CpG portion. 
Circles which are crossed out stand for undefined CpG methylation status. Arrows indicate the transcription 
start site of CBS gene.
www.nature.com/scientificreports/
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Figure 5. Detailed analysis by bisulfite sequencing of CpG island methylation patterns within 5′ regulatory 
region of MTHFR gene in early urothelium carcinoma. Stage and grade of UC tissue specimens with sample 
IDs (Table 1) are depicted above the panels. Exemplarily, above the first two panels, two corresponding array 
results are shown by bar plots. Each blue bar represents a 75 bases long CpG-rich probe on the array. The high of 
a bar is proportional to the methylation degree. Underneath the detailed CpG methylation profiles of the CpG-
rich 5′ regulatory region of MTHFR gene are documented as they were revealed by bisulfite sequencing. Filled 
rectangles stand for methylated cytosine outside the CpG context. White rectangles stand for unmethylated 
cytosine. White circles stand for unmethylated CpG dinucleotides. Arrows indicate the transcription start site of 
MTHFR gene. Underneath the upper left panel the positions of the differentially methylated cytosines relative to 
transcription start site are depicted.
Figure 6. Relative quantification of LINE-1 methylation in UC. LINE-1 methylation was measured by real 
time IDLN-MSPCR in three healthy- and in eight pTa-, six pT1- and one pT3 UC samples, each with the 
corresponding sample ID (Table 1). Significant differences between the two groups (p < 0.05) were verified by 
the Student’s t-test*.
www.nature.com/scientificreports/
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in most of the analyzed early urothelial carcinoma specimens would be expected to epigenetically impair ODC1 
expression.
Second, we have documented here DNA methylation of the 5′-regulatory region of AHCY encoding 
S-adenosylhomocysteine hydrolase in urothelial carcinoma specimens. Like ODC1, AHCY is transcribed from a 
single CpG-island promoter. In mammals, AHCY is the only known enzyme that catalysis the hydrolysis of SAH 
to homocysteine and adenosine, thereby relieving the inhibitory effect of SAH37. AHCY downregulation was 
previously shown to contribute to global DNA hypomethylation38 and to tumorigenesis, by conferring resistance 
to p53 and p16INK4-induced proliferation arrest39. Moreover, inhibition of S-adenosyl-L-homocysteine hydrolase 
and the resulting increase in SAH levels were shown to elicit DNA hypomethylation in cultured endothelial 
cells40. AHCY mRNA was found lost in 50% of tumor tissues from 206 patients with different kinds of tumors in 
comparison to their normal tissue counterparts; downregulation was found in 14 different tumor entities, includ-
ing renal carcinoma, but unfortunately UC was not investigated in that study39. Taken together, these obser-
vations actually hint at a tumor suppressor function for AHCY, which is largely unexplored. Our observation 
of dense DNA methylation in the AHCY promoter suggests that also AHCY transcription too is epigenetically 
impaired in early UC. This could lead to SAH accumulation and DNA hypomethylation and might contribute to 
tumorigenesis.
Third ,  Met hy lenete t ra hydrofol ate  re duc t as e  (MTHFR)  c at a lyzes  t he  convers ion  of 
5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-substrate for remethylation of homocysteine 
to methionine. There is overwhelming evidence that reduced MTHFR expression in diverse tumor entities leads 
to homocysteine accumulation and DNA hypomethylation41. In various cases genetic polymorphisms, e.g. the 
two common functional polymorphisms A1298C (rs1801131) and C677T (rs1801133) which diminish enzy-
matic activity, are involved. For instance, carriers of the MTHFR variant allele A1289C had 4% lower LINE-1 
methylation compared to those carrying the more common genotypes of this SNP in histologically normal breast 
tissues42. Interestingly, this allele was reported to confer a 4.76-fold increased risk of developing bladder cancer43. 
Decreased expression of MTHFR may also occur as a consequence of promoter hypermethylation. The 5′-region 
analyzed by us was identified as the site of focal epimutations in mothers of Down syndrome children associated 
with global LINE-1 hypomethylation in their blood cells44. Noteworthy, we demonstrate by a reporter assay that 
this region has promoter activity and is repressed by DNA methylation (Suppl. Figure 2c). In human lung cancer 
cells MTHFR methylation was inversely correlated with gene expression45. The increased methylation found in 
our study was also unusually caused by focal methylation of specific non-CpG-sites in the MTHFR 5′-regulatory 
region. Two of them form, according to in silico prediction, parts of GRα binding sites. GR expression tends to 
be weaker in bladder cancer tumors than in normal cells, and strong GR expression tends to be correlated with 
a better prognosis46. In addition, systemic use of glucocorticoids has been linked to an increased risk of bladder 
cancer47. Focal cytosine methylation at transcription factor binding sites may lead to altered gene expression48.
Taking together, we present evidence that in early UC altered DNA methylation occurs at genes encoding key 
factors of methyl group metabolism. Their altered expression is expected to interfere with methylome integrity 
and in a feed-forward loop may propagate the development of epigenetic abnormalities, e.g. LINE-1 hypometh-
ylation and other epigenetic disturbances in early urothelial carcinoma. Indeed, we detected marked LINE-1 
hypomethylation in UC samples which concomitantly exhibit DNA methylation of methyl group metabolic genes 
(Fig. 6).
On the basis of our study we suggest here the following hypothesis, named PrimeEpiHit (PEH) hypothesis as 
initial part of the molecular etiology of urothelial carcinoma.
Carcinogenic substances, e.g. aromatic amines from cigarette smoke exert their dangerous influence via the 
urine on urothelial cells. They are able to cross the cellular membranes, hit, react with and affect the genetic mate-
rial. In particular they chemically interact with DNA to form mutagenic adducts and may interfere with proper 
transcription.
Due to the chronic character of this influence, occasionally also genes with key functions in methyl group 
metabolism are affected, by impairment of their transcription and subsequently altered epigenetic status. This 
impairment causes regulation imbalances within the involved methyl group metabolic pathways, disturbances 
of the delicate SAM:SAH ratio and consequently genome-wide DNA methylation alterations, including LINE-1 
hypomethylation, ultimately resulting in genetic instabilities and cellular transformation. Noteworthy, this fatal 
development could be in parallel enhanced by the well described aging-dependent deficits of methyl group 
metabolism which are likewise characterized by an enhanced accumulation of SAH and DNA hypomethylation49. 
Age is also an important risk factor for bladder cancer1. Finally, it should be noted that such epigenetic alterations 
of genes with key importance in methyl group metabolism appear to fit well with the broadly discussed “few 
hits”-theory of cancer initiation. Here it has been suggested that for the most cancers few genetic, e.g. 6 for colon 
cancer, and in addition epigenetic events are together responsible for cancer initiation50.
Methods
Preparation of DNA from formalin-fixed, paraffin-embedded (FFPE) tissue samples and 
punches. agenode) according to the All methods were carried out in accordance with relevant guidelines 
and regulations. We confirm that the experimental protocols were approved and informed consent was obtained 
from all participants. An appropriate ethics vote was granted by the Kantonale Ethikkommission Zürich on 
22.02.2013, Ref. Nr. KEK-ZH-Nr 2012–0352. Histological H&E stained sections from formalin-fixed paraf-
fin-embedded (FFPE) tissue specimens (UC and non-dysplastic urothelium of individuals without a history of 
UC) were reviewed for tumor and urothelium content and the target area was marked by a trained pathologist 
(Dr. Jankowiak, Dr. Braunstein, Dr. Anlauf, Dr. Wild or Dr. Buser) for tissue punching using a hollow needle. 
DNA from FFPE punches (3 cylinders with diameter of 0.6 mm and a length of 2–3 mm) was isolated using the 
Maxwell 16 FFPE Tissue LEV DNA Purification Kit (Promega, Madison, United States, #AS1130) according 
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to the manufacturer’s recommendations. Briefly, FFPE cylinders were deparaffinised with xylene, washed twice 
with ethanol, dried 10 min at 37 °C and resuspended in 200 μl incubation buffer containing 2 mg/ml proteinase 
K. Samples were incubated overnight at 70 °C and mixed with 400 μl lysis buffer. Lysates from FFPE tissue were 
transferred to well 1 of the supplied cartridge of the corresponding kit and DNA was automatically purified and 
eluted in 30 μl Tris-buffer, pH 8.0 by the Maxwell instrument. The yield ranged between 1 and 8 µg of high quality 
DNA per sample. Purity control and quantification were performed using a NANODROP 2000 UV-Vis spec-
trometer (Thermo SCIENTIFIC, Wilmington, USA). Table 1 and Fig. 7 provide an overview of all used clinical 
samples and representative histological images (Table 1, Fig. 7). Overall we obtained five punches from multifocal 
UC tissue and five punches from the respective adjacent, benign urothelial tissue. These 5 UC punches consisted 
of 2pTa low grade, 1pTa high grade and 2 pT1 high grade tumors. Furthermore we obtained one microdissected, 
unifocal, pTa low grade UC tissue sample, eight punches of early unifocal UC and four punches with respective 
adjacent, benign urothelial tissue. In addition, we obtained one microdissected pT3 high grade unifocal UC tis-
sue sample. As references we obtained two paraffin-embedded, microdissected tissue samples and two punches 
of healthy urothelium. The eight punched samples of early unifocal UC were three pTa low grade, two pTa high 
grade, one pT1 low grade and three pT1 high grade tumors. Each of the few samples for microdissection was 
pathologically reviewed and the marked region of interest was cut into 5 µm slices which were transferred into 
Eppendorf reaction tubes. Tissue was dewaxed by incubation in xylene 2 times for 10 minutes followed by etha-
nol series 100% to 60% for 5 min each. Samples were cleaned in bidest. H2O and dried at RT. Cellular DNA was 
isolated using the OIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocols.
Figure 7. Representative pictures of pathologically classified tissue samples used for methylation analysis.
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Methylated DNA Immunoprecipitation (MeDIP). Genomic DNA (1 µg) dissolved in a final volume of 
100 µl was sonicated at 4 °C in TPX® polymethylpentene tubes using a Bioruptor® sonicator (Diagenode, Liege, 
Belgium) in order to produce random sized fragments ranging from 300–1.000 bp. Twenty sonication pulses of 
each 15 sec were applied. Immunoprecipitation (IP) of methylated DNA was then performed by magMeDIP kit 
(Diagenode) according to the manufacturer’s instructions. Briefly, DNA samples at a final concentration of 0.1 µg/
µl were denatured at 95 °C for 3 min., quickly chilled on ice and immunoprecipitated by adding 20 µl magnetic 
bead-immobilized 5-methylcytosine (5-mC) monoclonal 33D3 antibody (Diagenode). The bound DNA was sep-
arated from the beads by incubation with proteinase K at 55 °C for 15 min. Control input samples contained 20% 
of the corresponding DNA sample used for IP.
Amplification and labelling of DNA. Whole genome amplification of the input DNA and the immuno-
precipitated DNA samples was performed applying the Genome Plex Complete WGA Kit (Sigma-Aldrich, St. 
Louis, United States) as described by the user’s guide. The amplification products were purified using QIAquick 
PCR Purification Kit (Qiagen, Hilden, Germany). Input and IP DNA were labeled with Cyanine 3 and Cyanine 5, 
respectively, using random primers and Klenow fragment polymerase. Labeling was performed using the SureTag 
Complete DNA Labeling Kit (Santa Clara, CA), as suggested by the manufacturer. Labeled DNA was cleaned with 
70% ethanol and dried using a vacuum centrifuge for few minutes.
Hybridization of microarrays. Equal amounts of labeled IP and input DNA (700 ng) were combined and 
loaded on NimbleGen 385 K RefSeq Promoter Arrays HG18, containing all known human RefSeq genes (Roche, 
Basel, Switzerland) or NimbleGen Human DNA Methylation 2.1 M Deluxe Promoter Arrays. Initially, tissue 
samples from Düsseldorf were analyzed by NimbleGen 385 K Arrays; after the upgraded, high resolution 2.1 M 
NimbleGen Array became available, tissue samples from Zürich were analyzed on these arrays.
On both arrays all known gene 5′-regulatory regions are covered by 75-mer probes with approximately 100-bp 
spacing. The 385 K arrays cover a region between 2.2 kb downstream and 0.5 kb upstream of the transcription 
start site. The 2.1 M arrays cover a region between 7.25 kb downstream and 3.25 bp upstream of the transcription 
start site. The hybridization procedure was executed at 42 °C for 16 h in the NimbleGen hybridization chamber in 
accordance with the manufacturer’s protocol. The hybridized arrays were washed thoroughly and dried using a 
microarray centrifuge for 1 min in the dark.
DNA methylation microarray scanning and data analyses. The hybridized arrays were scanned on 
an MS200 microarray scanner (Roche, Basel, Switzerland) at a resolution of 2 µm. The raw methylation data were 
extracted with the default ChIP protocol from software NimbleScan for 385 K arrays and with DEVA for 2.1 M 
arrays. Methylation ratios between the IP DNA samples and the control input samples were normalized across 
samples using the quantile method after performing a variance stabilization using log2 scaling for each promoter 
feature on the array. All data processing including mapping of microarray probes to promoters, gene annotation, 
data post-processing, principal component analysis, identification of differentially methylated regions, and graph-
ics were performed with in-house developed functions in Matlab51,52.
Determination of differentially methylated regions (DMRs) of gene promoters. The promoter 
loci information on the DNA methylation microarray probes was taken from NimbleGen annotation information 
based on RefSeq version MM9. For each selected pair of sample subgroups, we calculated the mean of each probe 
across all samples of the subgroup. To address the statistical significance of the differently methylated regions 
(DMRs) we applied the two-samples Student’s t-test with a significance threshold αDMR = 0.05. The level of 
significance was set to p < 0.05. This means that a gene with such a value has a probability of >95% to show signif-
icant hypermethylation within the appropriate group by direct comparison to the reference group.
Bisulfite genomic sequencing. Bisulfite sequencing was performed following bisulfite conversion with 
the EpiTec Kit (Qiagen, Hilden, Germany) as described (Santourlidis et al. 2002, Ghanjati et al.)10. Primers were 
designed after excluding pseudogenes or other closely related genomic sequences which could interfere with spe-
cific amplification by amplicon and primer sequences comparison in BLAT sequence data base (https://genome.
ucsc.edu/FAQ/FAQblat.html). The following PCR primers for amplification of AHCY, CBS, MTHFR and ODC1 
5′-regulatory gene regions by nested PCR have been used (Table 2).
In brief, the pre-amplification conditions were denaturation at 95 °C for 13 min. followed by 22 cycles of 95 °C 
for 50 s, TM for 45 s (AHCY: 56 °C; CBS: 54 °C; MTHFR: 51 °C; ODC1: 52 °C), and 72 °C for 30 s. For the sec-
ond round of the applied nested PCR the pre-amplification product was diluted 1:10 and the same PCR condi-
tions were chosen for 35 additional cycles with the second primer pair. The amplification products were 348 bp 
(AHCY), 362 bp (CBS), 450 bp (MTHFR) and 224 bp (ODC1) in size. Amplification products were cloned into 
pCR2.1 vector using the TA Cloning Kit (Invitrogen, Carlsbad, United States) according to the manufacturer’s 
instructions. On average 30 clones were sequenced using the BigDye Terminator Cycle Sequencing Kit (Applied 
Biosystems, Foster City, United States) on a DNA analyzer 3700 (Applied Biosystems) with M13 primer to obtain 
a representative methylation profile of each sample. 5′-regulatory gene sequences refer to +1 transcription start 
of the following sequences:
Homo sapiens ornithine decarboxylase 1 (ODC1), transcript variant 1, mRNA
NCBI Reference Sequence: NM_002539.2
Homo sapiens adenosylhomocysteinase (AHCY), transcript variant 1, mRNA
NCBI Reference Sequence: NM_000687.3
Homo sapiens methylenetetrahydrofolate reductase (NAD(P)H) (MTHFR), mRNA
NCBI Reference Sequence: NM_005957.4
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Homo sapiens cystathionine-beta-synthase (CBS), transcript variant 1, mRNA
NCBI Reference Sequence: NM_000071.2
Relative Quantification of LINE-1 methylation in UC and reference samples by real-time 
MSP. Real time Methylation-Specific PCR of differentially methylated LINE-1 promoter regions was per-
formed as following: Converted DNA of the used tissue samples served as template for amplification of meth-
ylated LINE-1 sequences in a normalized real time MSP approach for genetic imbalanced DNA specimens as 
described (Santourlidis et al.)24. The primers listed below have been used (Table 3).
The amplification conditions were denaturation at 95 °C for 10 min, followed by 40 cycles of 95 °C for 30 s, 
TMs: 61 °C for 40 s (L1met) or 58 °C for 40 s (L1control) and 72 °C for 15 s.
Luciferase reporter assay and cell lines. The human epithelial, embryonal kidney cell line HEK 293 T, 
established from a human primary embryonal kidney transformed by adenovirus type 5 was cultured according 
to the manufacturer’s recommendation in high glucose DMEM GLUTAMAX (Gibco, Waltham, United States) 
containing 10% FCS (Gibco) and 1% penicillin and streptomycin at 37 °C and with 5% CO2.
The gene promoter fragments were amplified using the primers listed below and cloned into the pGL3 basic 
vector using the restriction enzymes XhoI and HindIII (NEB, Ipswich, United States). All constructs were vali-
dated by sequencing. For analysis of the influence of promoter methylation the constructs were in vitro methyl-
ated by using the CpG methyltransferase M. SssI (NEB).
For the Luciferase Assay the cells were seeded into 48-well plates. The cells were cotransfected with each 50 ng 
of the pGL3 basic vector (Promega, Madison, United States) and pTK-Green Renilla vector (Invitrogen, Carlsbad, 
Primer Name Sequence Product Length
s1AHCYkonv 5′–ATTTTGAGGTTTTTTTTTAGGGA–3′ 348 bp
as1AHCYkonv 5′–TTCCAAAAAATCCAAAAAACC–3′
as2AHCYkonv 5′–CAAAAAATCCAAAAAACCCCC–3′
s1CBSkonv 5′–GTGATTTTAAGGGGGTTTTG–3′ 362 bp
s2CBSkonv 5′–ATTTTAAGGGGGTTTTGTG–3′
as1CBSkonv 5′–TCTAACACAAACCCTATCTAACC–3′
as2CBSkonv 5′–CACAAACCCTATCTAACCTAAAA–3′
s1MTHFRkonv 5′–TAGGAGGGGTTATGAGAAAAGAT–3′ 450 bp
s2MTHFRkonv 5′–GAGGGGTTATGAGAAAAGATTTT–3′
as1MTHFRkonv 5′–TCCTAATCTCAATCCCAAAACTC–3′
as2MTHFRkonv 5′–ACTCCTAATCTCAATCCCAAAAC–3′
s1ODC1konv 5′–GGTTTTGTTAGTTTTTTTTGTA–3′ 224 bp
s2ODC1konv 5′–TTTTGTTAGTTTTTTTTGTAGT–3′
as1ODC1konv 5′–AAAAATCCCTCACCTCAA–3′
as2ODC1konv 5′–AAATGCCTCACCTCAAAA–3′
Table 2. Primers used for bisulfite genomic sequencing.
Primer Name Sequence Product Length
sL1met 5′-GCGCGAGTCGAAGTAGGGC-3′ 193
asL1met 5′-CTCCGACCAAATATAAAATATAATCTCG-3′
sL1control 5′-AGGTTTTATTTTTGGGGGTAGGGTATAG-3′ 207
asL1control 5′-CCCCTACTAAAAAATACCTCCCAATTAAAC-3′
Table 3. Primers used for LINE-1 real time Methylation-Specific PCR.
Primer Name Sequence Product Length/TM
s1ODC1 5′-CCGCTCGAGCGGATAAGTAGGGAGCGGCGTG-3′ 298 bp/58 °C
as1ODC1 5′-CCCAAGCTTGGGCTCCCTCCCTTCCTCCG-3′
s1AHCYRS 5′-CCGCTCGAGCGGAGTTCCGCTGGGTTTTGAC-3′ 503 bp/60 °C
as1AHCYRS 5′-CCCAAGCTTGGGATTCCAGGGGGTCCAGAGA-3′
s2MTHFRRS 5′-CCGCTCGAGCGGCCAGGAGGGGTTATGAGAAAAGAC-3′ 456 bp/62 °C
as2MTHFRRS 5′-CCCAAGCTTGGGCTCGCCCCACCCGTCTG-3′
Table 4. Primers used for luciferase reporter assay.
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United States). Lipofectamine 2000 (Invitrogen) was used as transfection reagent according to the manufacturer’s 
suggestion. The following primers have been used (Table 4).
The Luciferase Assay was performed with the Dual Luciferase Reporter Assay system (Promega) according 
to the manufacturer’s guideline. In short, growth medium was removed and the cells were washed with PBS 
(Gibco). To each well 65 µl of passive lysis buffer was dispensed and the cells were incubated for 15 minutes at 
room temperature on a rocking platform. Twenty µl of cell lysate were then transferred into each luminometer 
tube and 100 µl Luciferase Assay Reagent II was added. Firefly luciferase activity was measured by a 2-second 
premeasurement delay, followed by a 10-second measurement period for each reporter assay with the Lumat 
LB 9507 (Berthold Technologies, Bad Wildbad, Germany). The firefly luciferase reaction was stopped by adding 
100 µl Stop & Glo reagent and Renilla luciferase activity was measured.
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